BARTEK-INGREDIENTS
25.1.2023 21:05:42 CET | Business Wire | Press release
Bartek Ingredients advances its plans to strengthen its position as the world’s largest producer of malic and food-grade fumaric acid with the groundbreaking of its state-of-the-art, $175 million malic and fumaric acid production facility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005653/en/
Left to right: Tim Larson (Bartek), Minister Neil Lumsden, MP Chad Collins, Minister Lisa Thompson, Hamid Goli (Bartek), Jose Kafie (Bartek), John Burrows (Bartek), Jim Vincent (Bartek), Steven Chambers (Bartek), Minister Vic Fedeli. (Photo: Business Wire)
The company held a groundbreaking ceremony on Jan. 12 with Canadian government officials and local community leaders to celebrate the official commencement of the construction project.
“We are thrilled to be breaking ground on our new facility which will set a new global benchmark for safety, efficiency, and environmental performance,” Bartek President and CEO John Burrows said. “We are pleased to be investing in the community of Stoney Creek and proud to play an integral part in supporting local industries and the local economy. We are thankful for our partnerships with the provincial and federal government and Environment Hamilton and their support and guidance throughout the process.”
Among those in attendance at the groundbreaking were Neil Lumsden, Minister of Tourism, Culture and Sport and Member of Provincial Parliament for Hamilton East, Victor Fedeli, Minister of Economic Development and Trade, Lisa Thompson, Minister of Agriculture, Food and Rural Affairs, and Chad Collins, Member of Federal Parliament for Hamilton East-Stoney Creek.
“Congratulations to everyone at Bartek Ingredients on this exciting milestone,” Minister Fedeli said. “Bartek’s $175 million investment will ensure that the company can continue to expand and create more good-paying jobs in Hamilton and the surrounding region. Together, we’re building a stronger Ontario with opportunities for all people.”
The facility will double Bartek’s production capacity and propel new product development and other innovation efforts. It is also being built with sustainability in mind and is expected to be the most environmentally sustainable facility in the industry – projected to reduce per unit greenhouse gas emissions by more than 80 percent.
“Ontario has a clean energy advantage and is a sustainable and predictable place to do business,” Minister Piccini said. “As a result, we’re attracting the jobs of tomorrow. My Ministry was proud to work closely with Bartek through the permitting and approvals process to help secure this significant investment to Ontario.”
Minister Thompson added: “Bartek’s new state-of-the-art facility will be a shining example of Ontario’s robust agri-food manufacturing and processing sector. This major investment will create good-paying jobs in the local community and further strengthen Ontario’s value-added food supply chain.”
Through this project, Bartek will inject $100 million into the local Stoney Creek economy. The facility is expected to be fully operational at the beginning of 2024.
“Hamilton’s Bartek facility will soon become one of the world’s largest malic and food-grade acid production plants,” Minister Lumsden said. “Our government is excited to see local manufacturers, such as Bartek, invest in Ontario to grow and create more good-paying jobs right here in Hamilton!”
For more information, please visit bartek.ca or contact Bartek at info@bartek.ca.
About Bartek Ingredients
For over 50 years, Bartek Ingredients Inc. has been a leading global manufacturer of malic acid, fumaric acid, and maleic anhydride. Headquartered in Stoney Creek, Ontario, Canada, Bartek employs 120 people across its two production facilities in Southern Ontario. Bartek’s facilities are registered to the ISO 9001:2015 Standard. Bartek also holds the BRC Global Standard for Food Safety certification, and it distributes to more than 40 countries around the world. With new ownership in 2019 and significant investments, Bartek’s presence in the food and beverage space continues to be bolstered by highly innovative products and services that utilize deep product expertise and application knowledge to offer solutions to industry needs. For more information about Bartek, visit bartek.ca/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005653/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release
Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
